Japanese Encephalitis in Equines

Amna Tabassum[1,*], Ayah Talal Zaidalkilani[2], Ammar AL-Farga[3], Shamreza Aziz[4] and Qamar un Nisa[5]

[1]KBCMA, College of Veterinary & Animal Sciences, Narowal, Sub-campus UVAS-Lahore, Pakistan
[2]Faculty of Pharmacy and Medical Sciences, Department of Nutrition, University of Petra, Amman, Jordan
[3]Department of Biological Sciences, College of Science, University of Jeddah, Jeddah, Saudi Arabia
[4]Department of Epidemiology and Public Health, University of Veterinary and Animal Sciences, Lahore, Pakistan
[5]Department of Pathology, University of Veterinary & Animal Sciences, Lahore, Pakistan
*Corresponding author: tamna1560@gmail.com

Abstract

The mosquito-borne flavivirus known as the Japanese encephalitis (JE) virus was initially identified in Japan in 1935 after being isolated from the brain tissue of a patient who had died of encephalitis. A vector association was indicated by the disease's seasonal prevalence in Japan, and the virus was identified from *Culex tritaeniorhynchus* mosquitoes in early 90s. Even though there had been small outbreaks of "summer encephalitis" in Japan as early as 1870, the illness received little notice until the massive outbreak in 1924, which claimed 6125 lives and caused 3797 cases. Since the late 1960s, northern Thailand has seen a predictable pattern of recurring yearly epidemics, in contrast to the endemic pattern of southern Thailand. Japanese encephalitis is a serious health related issue, especially in South and Southeast Asian poorer nations. JE must be treated with supportive and symptomatic interventions as well as preventative measures in the absence of targeted antiviral medication. It is challenging to implement strategies including environmental modification, vector control, and agricultural practice changes. Economically developed nations' control of JE points to the importance of socioeconomic elements such as knowledge and cleanliness. Meanwhile, the hunt for affordable therapy and vaccination plans must continue.

Keywords: Japanese encephalitis virus, Symptomatic interventions, Zoonoses, Encephalitis, Mosquitoes.

Cite this Article as: Tabassum A, Zaidalkilani AT, AL-Farga A, Aziz S and Nisa QU, 2025. Japanese encephalitis in equines. In: Abbas RZ, Akhtar T and Jamil M (eds), Pathways of Infection: Zoonoses and Environmental Disease Transmission. Unique Scientific Publishers, Faisalabad, Pakistan, pp: 207-211. https://doi.org/10.47278/book.HH/2025.356

A Publication of Unique Scientific Publishers

Chapter No: 25-029

Received: 15-Feb-2025
Revised: 14-Apr-2025
Accepted: 25-May-2025

Introduction

Japanese encephalitis (JE) virus is a mosquito-borne flavivirus that may cause encephalitis and mortality in both equines and people. This new illness is causing international worry as it spreads to formerly non-endemic places. Over the last 30 years, its range has increased to include Nepal, Pakistan, Papua New Guinea, and northern Australian islands (Quan et al., 2020). In the second half of the nineteenth century, epidemics of "summer encephalitis" in Japan led to the first reports of what is now known as the Japanese encephalitis virus (JEV). Early in the 1930s, the virus became identifiable and initially passed in mice and monkeys (Walsh et al., 2022). Culex mosquitoes spread JEV, a flaviviridae virus that affects people as well as pets. JEV was first detected from the brain of a fatal case of JE in 1935, whereas JE was originally documented in Japan in 1871. This segregate is recognized as the JEV template strain and is referred to as the Nakayama strain (Mackenzie et al., 2022).

History

Japanese encephalitis was identified in both equines and people in the early 80s. In 1924, a serious pandemic was recorded in Japan. An accessible substance was taken from the human central nervous system and transmitted to rabbits, but the agent remained unidentified. Every ten years, Japan has large epizootics that afflict over 6500 patients (Ellis et al., 2000; Campbell et al., 2011). In 1930, Hyashi used intracerebral injection to replicate the sickness in monkeys. In 1935, JE virus was identified from a human brain in Tokyo, Japan. The Nakayama strain was created as the virus's virological and serological prototype. JEV was isolated from a sick horse's brain in 1937. Mitamura and coworkers identified Japanese encephalitis virus from *Cx. tritaeniorhynchus* after suspecting mosquito spread in the beginning of the nineteenth century (Quan et al., 2020). Pigs and birds serve as reservoirs for Japanese encephalitis virus spread, as developed in 1959 (Mackenzie et al., 2004; Tiwari et al., 2012).

Pathogenesis

For the virus to reproduce once a mosquito draws blood from an infected host, it must first overcome a number of physiological and physical obstacles. If the peritrophic membrane, a possible physical barrier, has not yet developed, the virus's envelope unites with the intestinal epithelial cells' plasma membrane once it reaches the midgut, releasing its DNA into the cytoplasm (Mohsin et al., 2022). The virus then multiplies and releases virions into the hemocoel, where they go to the tracheal system and ultimately the salivary glands. After successfully overcoming the salivary gland infection barrier, the virus infects the acinar cells of the salivary glands and starts releasing

virions into the saliva. At this point, the infected mosquito is prepared to strike the next victim and infect them. A healthy individual gets bitten by a carrier mosquito, which releases virions into the skin cells. From there, the virus can either produce a chronic infection by invading the nervous system or an invisible infection by just penetrating mononuclear cells (Unni et al., 2011). The virus multiplies in monocytes in the bloodstream and macrophages found in tissues (Dutta et al., 2009). The virus may be eliminated prior it reaches the central nervous system if the immune system produces a humoral response (IgM) within the first five days of the virus's incubation duration (sub-clinical stage) (Sharma et al., 2021).

Additionally, JEV uses GKN3 and PLVAP receptors to enter neural cells. It then destroys neuronal cells and reduces the amounts of anti-inflammatory cytokines (IL-10 and IL-4) (Unni et al., 2011). By attaching to pathogen recognition receptors (PRR), pathogen-associated molecular patterns (PAMP) trigger interferon beneficial genes (ISGs), including PKR, OAS, TRIM21, ISG15, and MX1, through the JNK pathway. The virus can alter these interferons to its advantage, yet they cause the infected host cell and nearby undamaged host cells to go into an antiviral state. Integrated immune cells in the skin, including fibroblasts, dermal dendritic cells, epidermal cells, cells from the Langerhans family, and endothelial cells, are the main targets of the virus (Sharma et al., 2021; Kumar et al., 2022).

Pathology

Necropsy findings may reveal normal or hazy leptomeninges, as well as saturated parenchyma of the brain with blood spots or localized bleeding. The sores are primarily limited to the gray matter. Typically affected areas include the central nervous system and spinal cords anterior horn cells. Some postmortem samples show discolored grey matter in the spinal cord, indicating poliomyelitis (Misra & Kalita, 2010). Immunocytochemical investigations show JEV antigen distribution in neurons, particularly in the thalamus and medulla oblongata. In the cerebral cortex, the antigen was found in grainy and polymer neurons but not in crossing Purkinje neurons. JEV antigen was detected in neurons of the olfactory bulb. Tissue sample investigations have shown Purkinje neuron loss as a hallmark of Japanese encephalitis autopsy (Solomon & Vaughn, 2002; Misra & Kalita, 2010). Real-time polymerase chain reaction (Rt-PCR) investigations in rats revealed that the JEV RNA copies were present in the thalamus, striatum, brainstem, and cerebral cortex by day six, but were no longer detectable by day twenty. JEV persists in the neurological system in five per cent of laboratory-confirmed cases of JE (Klein et al., 2019). A study of 159 individuals with Japanese encephalitis found that 61 (37.47%) had neurocysticercosis association. Neurocysticercosis was diagnosed via the cerebral spinal fluid immunoglobulin in forty-five cases, a cranial computed tomography scan in six, and an autopsy in three patients. Pork tapeworm in Japanese encephalitis was linked with adverse outcomes (Desai et al., 1997). Attacking distinct structural and non-structural proteins can stop the virus's reproduction at different phases, according to research on the JEV life cycle. It is possible to investigate structural proteins, like capsid and envelope proteins, and non-structural proteins, containing NS3 and NS5, as distinct therapeutic targets (Ishikawa & Konishi, 2015).

Clinical Manifestations

Depending on which region of the nervous system is impacted, the disorder can present with initial signs like diarrhea and rigorousness, which are vague febrile illnesses, which are followed by complications like reduced awareness, convulsions, headaches, light sensitivity, and nausea (Solomon et al., 2000). Weird mental states can be seen in certain situations. Flaccid paralysis resembling poliomyelitis is another subsequent sign (Unni et al., 2011). Convulsions are more common in those with chronic encephalitis (Solomon, 2004). Patients eventually enter an acute coma in lethal circumstances. The existence of epileptiform disorders and alpha, theta, and delta coma are among the several electroencephalographic abnormalities (Kalita & Misra, 2000b). A brainstem infection manifests as anomalies in the papillary and oculocephalic reflexes, flexor and extensor posture, and breathing rhythm (Solomon et al., 2000). The brain exhibits severe levels of vascular congestion, microglial expansion, creation of glial mesenchymal lumps, confined or merged areas of swollen necrosis, cerebral fluid buildup, and trans-compartmental alteration in deadly episodes of JEV. These neurological alterations are diffuse and multifaceted, affecting different parts of the neurological system (Ghosh & Basu, 2009). In addition to being a murderer, JE may also inflict a great deal of social and economic hardship, particularly in underdeveloped nations, since many survivors experience neuropsychiatric repercussions with cognitive and linguistic dysfunction (Kaur & Vrati, 2003).

Diagnosis

Japanese encephalitis patients have acute encephalitis syndrome symptoms. Since there are several potential causes of acute encephalitis syndrome, laboratory confirmation is necessary for a precise classification of JE. However, due to the extremely low viremia, this is a challenging process. Therefore, the goal of diagnosis is to find antibodies in serum and cerebral fluid. When antibodies to other flaviviruses cross-react, it might be confusing to diagnose JEV. The World Health Organization (WHO) has established criteria that must be met in order to identify an event as JE, as well as surveillance guidelines for the detection of JEV and suggested incidence definitions of Japanese encephalitis. Japanese encephalitis patients have acute encephalitis syndrome symptoms (Chung et al., 2007; Solomon et al., 2008). A widely utilized diagnostic technique for Japanese encephalitis discovery is IgM Capture Immunoassay (Shrivastva et al., 2008). Many advances have been made recently in techniques that facilitate early JEV detection, such as the dipstick approach (Ravi et al., 2006) JEV-CheX is a rapid ELISA kit that detects IgM antibodies in human serum and cerebrospinal fluid (CSF) to identify JEV (Swami et al., 2008), and reverse transcriptase PCR (Lanciotti, 2003).

In an individual with encephalitis from a region where JE is indigenous, a simultaneous thalamus lesion is very indicative of JE. Subsequent investigations Within a few months, an MRI shows that the acute lesions that are restorative on T1 and T2 sequences have shrunk. In a research comparing computed tomography with magnetic resonance imaging, fifty-five percent of the CT scans were aberrant. All patients had aberrant MRI results, with ninety-four percent showing ventricular lesions, thirty-five percent showing basal ganglia, fifty-eight percent showing midbrain, twenty-six percent showing pons, and 19% showing cerebellum and cerebral cortex (Kalita & Misra, 2000a; Handique et al., 2006). Thalamic hyperperfusion in acute stages of single photon emission computed tomography (SPECT) examinations, whereas inadequate

perfusion occurs in subacute or chronic stages. Thalamic hyperperfusion is shown in acute stages of single photon emission computed tomography (SPECT) examinations, whereas hypoperfusion occurs in subacute or chronic stages (Myint et al., 2007). Following JEV infection, there are humoral and cellular immunological responses. After a few days of the initial infection (first JEV infection), plasma and cerebrospinal fluid show a strong and quick immunoglobulin M response. All of the patients had increased immunoglobulin M concentrations by the 7th day (McGovern et al., 2007). Typically, the virus cannot be isolated from these patients; however, viral separation and death are linked to the inability to generate an IgM response (Tiroumourougane et al., 2002).

Differential Diagnosis

Equine herpes myeloencephalopathy, liver encephalopathy, fungal and chewing disease, bacterial meningitis, Neural angiostrongylosis, Equine protozoal myeloencephalitis (EPM), enzootic encephalomyelitis, equine encephalosis, and other Equine arboviral encephalomyelitis are among the various causes of diffuse cerebral disease that must be distinguished from JE in horses. Additionally, rabies, botulism, and several plant and chemical poisons ought to be classified as OUU (Solomon, 2003; Maschke et al., 2004).

Treatment

Horses with viral encephalitis do not have a particular treatment; instead, supportive care is the mainstay of care. Pyrexia, swelling, and pain can all be managed with nonsteroidal anti-inflammatory medications. To reduce inflammation and offer some relaxation and moderate drowsiness, dimethyl sulfoxide (1 g/kg in 20'X solution) can be administered intravenously. Anticonvulsant medications and brief glucocorticoid usage may also be helpful. Additional supportive treatment consists of enteral or parenteral nutrition, hydration therapy, laxatives to reduce the danger of gastrointestinal impaction, and defense against damage caused by oneself (Keiser et al., 2005; Leyssen et al., 2000). It has been demonstrated that curcumin, a plant-based chemical and antioxidant, inhibits the generation of new viruses by dysregulating the ubiquitin-associated protease system (Pryor et al., 2006; Dutta et al., 2009).

Vaccination

For equines, a formalin-inactivated culture of tissue vaccination made from japanese encephalitis virus-infected pig kidney cells obtained from the Beijing strain is sold professionally. In order to safeguard the health of communities of racehorse racehorses, many of whom are brought over from nations wherever japanese encephalitis does not exist, the vaccine is extensively utilized in Asian nations including Japan, Hong Kong, Macau, Malaysia, and Singapore (Schiøler et al., 2007). The initial course of immunization should be finished well in advance of the season when mosquito activity is at its highest for optimal protection (Bharati & Vrati, 2006). In contrast to naturally obtained neutralizing antibodies, which exhibited no such inhibitory effect, foals born to inoculated mares had antibodies from their moms that lasted for four to five months and impeded active vaccination (Saxena, 2008).

Future Perspectives

Investigation on flaviviral drugs is progressing quickly. We expect that a reliable chemotherapeutic drug to prevent flaviviral illnesses will shortly become available. Due to the preserved structure of the flaviviral proteins, investigations that has focused on West Nile virus (WNV), hepatitis C virus (HCV), dengue virus (DENV), and other viruses may be estimated to develop a medication designed specifically for JEV, even though it is currently not on the radar of large, envious drug-design projects. A future medication that targets the NS2B and NS3 nonstructural proteins of flaviviruses like the West Nile virus is being developed. This design highlights significant physicochemical and biological properties of proteases using crystallography-based algorithms of NS3 the base association molecules (Bessaud et al., 2006). Additionally, researchers are attempting to concentrate on the flaviviral capping enzyme (Chunprapaph et al., 2005). Another extremely potential target for upcoming medication development is the flavivirus's E and NS5 proteins. In order to better understand the biochemical characteristics, subcellular localization, and regulation of these proteins' inhibitors, research has clarified the crystal structure of their catalytically active sites. This has aided in the development of targeted inhibitors that would change the working structure of these proteins and, consequently, viral production (Kampmann et al., 2005; Malet et al., 2007).

Using attaching estimations, mean-field molecular dynamics techniques, Autodock as the virtual screening, and chemistry at Harvard macromolecular mechanics, a molecular dynamic tool, investigators are doing thorough computations to find novel drug-like compounds against WNV, yellow fever virus, dengue virus, and Hepatitis. This project's scope and depth hold considerable potential for a major advancement in the study of flaviviral drugs. Lastly, research showed that several groups of chemicals extracted from diverse plants, including lectins, lignans, thiophenes, polysaccharides, alkaloids, flavonoids, and terpenoids, have distinct antiviral characteristics and aim viral suppression (Jassim & Naji 2003).

Conclusion

The Japanese encephalitis virus is prevalent across Asia and predominantly causes human encephalitis, particularly in regions where the primary mosquito vector, *Cx. tritaeniorhynchus*, is abundant due to environmental factors. Nonetheless, a variety of household animals are prone to illness. Furthermore, pig farms' output may be lowered by livestock losses in the form of fetal deformities and mortality. Vaccination is the main method of preventing illness in livestock, especially pigs, however in many regions of Asia, farmers cannot afford it, thus it is not used. Pigs are not only a vulnerable host, but they may also serve as a reservoir host for JEV because of their high viraemia, which can further infect vectors that might then infect people. Even while JE can cause visceral inflammatory alterations, aseptic meningitis, or a slight fever, acute meningo-myeloencephalitis is by far the most significant pathological manifestation of infection in people. Seldom, if at all, can the JE virus become separated from peripheral blood during an individual's acute infection. This virus may be found in both human and animal samples using a variety of diagnostic techniques. To stop the disease from spreading, public health and veterinary officials should continue to be on the lookout for JEV.

References

Bessaud, M., Pastorino, B. A., Peyrefitte, C. N., Rolland, D., Grandadam, M., & Tolou, H. J. (2006). Functional characterization of the NS2B/NS3 protease complex from seven viruses belonging to different groups inside the genus Flavivirus. *Virus Research, 120*(1-2), 79-90.

Bharati, K., & Vrati, S. (2006). Japanese encephalitis: development of new candidate vaccines. *Expert Review of Anti-infective Therapy*, *4*(2), 313-324.

Campbell, G. L., Hills, S. L., Fischer, M., Jacobson, J. A., Hoke, C. H., Hombach, J. M., & Ginsburg, A. S. (2011). Estimated global incidence of Japanese encephalitis: a systematic review. *Bulletin of the World Health Organization*, *89*(10), 766-774.

Chung, C. C., Lee, S. J., Chen, Y. S., Tsai, H. C., Wann, S. R., Kao, C. H., & Liu, Y. C. (2007). Acute flaccid paralysis as an unusual presenting symptom of Japanese encephalitis: a case report and review of the literature. *Infection*, *35*(1), 30-32.

Chunprapaph, S., Sap Arpakorn, P., Sangma, C., Niyomrattanakit, P., Hannongbua, S., Angsuthanasombat, C., & Katzenmeier, G. (2005). Competitive inhibition of the dengue virus NS3 serine protease by synthetic peptides representing polyprotein cleavage sites. *Biochemical and Biophysical Research Communications, 330*(4), 1237-1246.

Desai, A., Shankar, S. K., Jayakumar, P. N., Chandramuki, A., Gourie-Devi, M., Ravikumar, B. V., & Ravi, V. (1997). Co-existence of cerebral cysticercosis with Japanese encephalitis: a prognostic modulator. *Epidemiology & Infection, 118*(2), 165-171.

Dutta, K., Ghosh, D., & Basu, A. (2009). Curcumin protects neuronal cells from Japanese encephalitis virus-mediated cell death and also inhibits infective viral particle formation by dysregulation of ubiquitin–proteasome system. *Journal of Neuroimmune Pharmacology*, *4*, 328-337.

Ellis, P. M., Daniels, P. W., & Banks, D. J. (2000). Japanese encephalitis. *Veterinary Clinics of North America: Equine Practice, 16*(3), 565-578.

Ghosh, D., & Basu, A. (2009). Japanese encephalitis—a pathological and clinical perspective. *PLoS Neglected Tropical Diseases, 3*(9), e437.

Handique, S. K., Das, R. R., Barman, K., Medhi, N., Saharia, B., Saikia, P., & Ahmed, S. A. (2006). Temporal lobe involvement in Japanese encephalitis: problems in differential diagnosis. *American Journal of Neuroradiology, 27*(5), 1027-1031.

Ishikawa, T., & Konishi, E. (2015). Potential chemotherapeutic targets for Japanese encephalitis: current status of antiviral drug development and future challenges. *Expert Opinion on Therapeutic Targets*, *19*(10), 1379-1395.

Jassim, S. A., & Naji, M. A. (2003). Novel antiviral agents: a medicinal plant perspective. *Journal of Applied Microbiology, 95*(3), 412-427.

Kalita, J., & Misra, U. K. (2000a). Comparison of CT scan and MRI findings in the diagnosis of Japanese encephalitis. *Journal of the Neurological Sciences, 174*(1), 3-8.

Kalita, J., & Misra, U. K. (2000b). Markedly severe dystonia in Japanese encephalitis. *Movement Disorders: Official Journal of the Movement Disorder Society, 15*(6), 1168-1172.

Kampmann, T., Yennamalli, R., Stoermer, M., Kobe, B., & Young, P. (2005). Development of antiviral drugs targeting the flaviviruses fusion mechanism. *Federation of European Biochemical Societies Journal, 272*(1), 553-553.

Kaur, R., & Vrati, S. (2003). Development of a recombinant vaccine against Japanese encephalitis. *Journal of Neurovirology, 9*(4), 421-431.

Keiser, J., Maltese, M. F., Erlanger, T. E., Bos, R., Tanner, M., Singer, B. H., & Utzinger, J. (2005). Effect of irrigated rice agriculture on Japanese encephalitis, including challenges and opportunities for integrated vector management. *Acta Tropica*, *95*(1), 40-57.

Klein, R. S., Garber, C., Funk, K. E., Salimi, H., Soung, A., Kanmogne, M., & Cain, M. (2019). Neuroinflammation during RNA viral infections. *Annual review of immunology*, *37*(1), 73-95.

Kumar, S., Verma, A., Yadav, P., Dubey, S. K., Azhar, E. I., Maitra, S. S., & Dwivedi, V. D. (2022). Molecular pathogenesis of Japanese encephalitis and possible therapeutic strategies. *Archives of Virology*, *167*(9), 1739-1762.

Lanciotti, R. S. (2003). Molecular amplification assays for the detection of flaviviruses. *Advances in Virus Research*, 61, 67-99.

Leyssen, P., De Clercq, E., & Neyts, J. (2000). Perspectives for the treatment of infections with Flaviviridae. *Clinical Microbiology Reviews*, *13*(1), 67-82.

Mackenzie, J. S., Gubler, D. J., & Petersen, L. R. (2004). Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. *Nature Medicine*, *10*(Suppl 12), S98-S109.

Mackenzie, J. S., Williams, D. T., van den Hurk, A. F., Smith, D. W., & Currie, B. J. (2022). Japanese encephalitis virus: the emergence of genotype IV in Australia and its potential endemicity. *Viruses*, *14*(11), 2480.

Malet, H., Egloff, M. P., Selisko, B., Butcher, R. E., Wright, P. J., Roberts, M., & Canard, B. (2007). Crystal structure of the RNA polymerase domain of the West Nile virus non-structural protein 5. *Journal of Biological Chemistry, 282*(14), 10678-10689.

Maschke, M., Kastrup, O., Forsting, M., & Diener, H. C. (2004). Update on neuroimaging in infectious central nervous system disease. *Current Opinion in Neurology*, *17*(4), 475-480.

McGovern, L. M., Boyce, T. G., & Fischer, P. R. (2007). Congenital infections associated with international travel during pregnancy. *Journal of Travel Medicine*, *14*(2), 117-128.

Misra, U. K., & Kalita, J. (2010). Overview: japanese encephalitis. *Progress in Neurobiology*, *91*(2), 108-120.

Mohsin, F., Suleman, S., Anzar, N., Narang, J., & Wadhwa, S. (2022). A review on Japanese Encephalitis virus emergence, pathogenesis and detection: From conventional diagnostics to emerging rapid detection techniques. *International Journal of Biological Macromolecules*, *217*, 435-448.

Myint, K. S. A., Gibbons, R. V., Perng, G. C., & Solomon, T. (2007). Unravelling the neuropathogenesis of Japanese encephalitis. *Transactions of the Royal Society of Tropical Medicine and Hygiene*, *101*(10), 955-956.

Nah, J. J., Yang, D. K., Kim, H. H., & Song, J. Y. (2015). The present and future of veterinary vaccines for Japanese encephalitis in Korea. *Clinical and Experimental Vaccine Research*, *4*(2), 130-136.

Pryor, M. J., Rawlinson, S. M., Wright, P. J., & Jans, D. A. (2006). CRM1-dependent nuclear export of dengue virus type 2 NS5. In "*New Treatment Strategies for Dengue and Other Flaviviral Diseases: Novartis Foundation Symposium," 277* (pp. 149-163). Chichester, UK: John Wiley & Sons, Ltd.

Quan, T. M., Thao, T. T. N., Duy, N. M., Nhat, T. M., & Clapham, H. (2020). Estimates of the global burden of Japanese encephalitis and the impact of vaccination from 2000-2015. *Elife, 9*, e51027.

Ravi, V., Desai, A., Balaji, M., Apte, M. P., Lakshman, L., Subbakrishna, D. K., & Ravikumar, B. V. (2006). Development and evaluation of a rapid IgM capture ELISA (JEV-Chex) for the diagnosis of Japanese encephalitis. *Journal of Clinical Virology, 35*(4), 429-434.

Saxena, S. K. (2008). Japanese encephalitis: perspectives and new developments. *Future Neurology*, *3*(5), 515-521.

Schiøler, K. L., Samuel, M., & Wai, K. L. (2007). Vaccines for preventing Japanese encephalitis. *Cochrane Database of Systematic Reviews*, (3).

Sharma, K. B., Vrati, S., & Kalia, M. (2021). Pathobiology of Japanese encephalitis virus infection. *Molecular Aspects of Medicine*, *81*, 100994.

Shrivastva, A., Tripathi, N. K., Parida, M., Dash, P. K., Jana, A. M., & Rao, P. L. (2008). Comparison of a dipstick enzyme-linked immunosorbent assay with commercial assays for detection of Japanese encephalitis virus-specific IgM antibodies. *Journal of Postgraduate Medicine, 54*(3), 181-185.

Solomon, T., & Vaughn, D. W. (2002). Pathogenesis and clinical features of Japanese encephalitis and West Nile virus infections. *Japanese Encephalitis and West Nile Viruses*, 171-194.

Solomon, T., Dung, N. M., Kneen, R., Gainsborough, M., Vaughn, D. W., & Khanh, V. T. (2000). Japanese encephalitis. *Journal of Neurology, Neurosurgery & Psychiatry, 68*(4), 405-415.

Solomon, T., Kneen, R., Dung, N. M., Khanh, V. C., Thuy, T. T. N., Ha, D. Q., & White, N. J. (1998). Poliomyelitis-like illness due to Japanese encephalitis virus. *The Lancet, 351*(9109), 1094-1097.

Solomon, T., Thao, T. T., Lewthwaite, P., Ooi, M. H., Kneen, R., Dung, N. M., & White, N. (2008). A cohort study to assess the new WHO Japanese encephalitis surveillance standards. *Bulletin of the World Health Organization, 86*, 178-186.

Solomon, T. (2003). Exotic and emerging viral encephalitides. *Current Opinion in Neurology*, *16*(3), 411-418.

Solomon, T. (2004). Flavivirus encephalitis. *New England Journal of Medicine, 351*(4), 370.

Swami, R., Ratho, R. K., Mishra, B., & Singh, M. P. (2008). Usefulness of RT-PCR for the diagnosis of Japanese encephalitis in clinical samples. *Scandinavian Journal of Infectious Diseases, 40*(10), 815-820.

Tiroumourougane, S. V., Raghava, P., & Srinivasan, S. (2002). Japanese viral encephalitis. *Postgraduate Medical Journal*, *78*(918), 205-215.

Tiwari, S., Singh, R. K., Tiwari, R., & Dhole, T. N. (2012). Japanese encephalitis: a review of the Indian perspective. *The Brazilian Journal of Infectious Diseases*, *16*(6), 564-573.

Unni, S. K., Růžek, D., Chhatbar, C., Mishra, R., Johri, M. K., & Singh, S. K. (2011). Japanese encephalitis virus: from genome to infectome. *Microbes and Infection*, *13*(4), 312-321.

Walsh, M. G., Pattanaik, A., Vyas, N., Saxena, D., Webb, C., Sawleshwarkar, S., & Mukhopadhyay, C. (2022). High-risk landscapes of Japanese encephalitis virus outbreaks in India converge on wetlands, rain-fed agriculture, wild Ardeidae, and domestic pigs and chickens. *International Journal of Epidemiology*, *51*(5), 1408-1418.